Denali, Takeda scrap PhI Alzheimer's drug due to safety signals, 'rapidly evolving' landscape

09 Aug 2023
endpts.com
Phase 1PROTACs
As Biogen takes a preclinical Denali compound targeting amyloid beta forward in Alzheimer’s, Denali is shelving another Alzheimer’s candidate that is partnered with Takeda and hits a different target.
Phase I data suggest that the drug, known as TAK-920 or DNL919, has a “narrow therapeutic window” given safety signals, Denali said. Together with Takeda, it now plans to go back to the drawing board, focusing on backup molecules still in the preclinical stage, including potential combinations.
Denali, Takeda scrap PhI Alzheimer's drug due to safety signals, 'rapidly evolving' landscape
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.